LC–MS Approach to Aid the Optimization of Biopharmaceutical Immunogenicity Assays
April 3rd 2014Scientists from Bristol-Myers Squibb Company have developed a novel approach for the simultaneous quantitation of neutralizing antibodies, residual drug, and human Immunoglobulin G (IgG) in immunogenicity assay development using liquid chromatography?tandem mass spectrometry (LC–MS–MS). This work published in Analytical Chemistry presents a new approach that aids the refinement of therapeutic protein neutralizing antibody assays in drug development.
Impact of New Columns on Drug Development
April 1st 2014An examination of the development of new types of columns based on different particle types, sizes, and other physical characteristics and how they can improve the speed and efficiency of HPLC used to support more expansive and complicated analyses